🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in France / NCT05197387
Recruiting Observational

Association of Intrahepatic Cholestasis of Pregnancy and Chronic Placental Inflammation

NCT05197387 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2022-06-21
Last updated
2024-10-16

Condition(s) studied

Cholestasis of Pregnancy

Study summary

This observational prospective study will help to determine if an immune process similar to allograft rejection is responsible for the occurrence of an intrahepatic cholestasis of pregnancy (ICP).

If so, it would suggest the potential benefit of immunomodulatory therapeutics.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adult pregnant woman with singleton For cases: diagnosis of intrahepatic cholestasis of pregnancy For controls: no diagnosis of ICP Exclusion Criteria: * Women under 18 years old * Women under legal protection * Gemellar pregnancies * Delivery before 22 Weeks of gestation * Medical termination of pregnancy * Acute chorioamniotitis, in particular those due to the following pathogens: toxoplasmosis, rubella, CMV, herpes virus * Premature rupture of membranes \<37SA * Women infected by covid-19 in the month before delivery

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
CHU Angers Angers France Not Yet Recruiting
Polyclinique KERAUDREN Brest France Recruiting
CHU de Brest Brest France Recruiting
CHU de Caen Caen France Recruiting
CH de Chambery Chambéry France Recruiting
CH Bretagne Sud Lorient France Recruiting
CHU Nantes Nantes France Recruiting
CH de Quimper Quimper France Recruiting
CHU de Rennes Rennes France Recruiting
CH St Brieuc Saint-Brieuc France Recruiting
CHU de Tours Tours France Recruiting

More University Hospital, Brest trials in France

Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii Active, not recruiting
Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis Active, not recruiting
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) Recruiting
Anatomical Assessment of Orbital Contents on Imaging (EACOI) Recruiting
Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05197387 on ClinicalTrials.gov ↗ ← All trials in France